Xenoport, Inc. (MM) (NASDAQ:XNPT)
Historical Stock Chart
5 Years : From Dec 2009 to Dec 2014
XenoPort, Inc. (Nasdaq: XNPT) announced today that it will provide
access via the World Wide Web to its presentation at the 23rd Annual
Piper Jaffray Health Care Conference. The live presentation will occur
at 7:30 a.m. Pacific Time (10:30 a.m. Eastern Time) on Wednesday,
November 30, 2011. A replay of the presentation will also be available.
To access the live presentation via the Web, please go to www.XenoPort.com.
Please connect to the Web site at least 15 minutes prior to the live
presentation to ensure adequate time for any software downloads that may
be necessary to listen to the Webcast.
A replay of the Webcast can be accessed for a minimum of one month and
will be available approximately 24 hours after the live presentation.
XenoPort is a biopharmaceutical company focused on developing and
commercializing a portfolio of internally discovered product candidates
for the potential treatment of neurological disorders. Horizant™
(gabapentin enacarbil) Extended-Release Tablets is XenoPort’s first
FDA-approved product. GlaxoSmithKline holds commercialization rights and
certain development rights for gabapentin enacarbil in the United
States. Gabapentin enacarbil is also being developed in partnership with
Astellas Pharma Inc. for the potential treatment of restless legs
syndrome in Japan. XenoPort holds all other world-wide rights and has
co-promotion and certain development rights to gabapentin enacarbil in
the United States. XenoPort’s pipeline of product candidates includes
potential treatments for patients with neuropathic pain, spasticity and
To learn more about XenoPort, please visit the Web site at www.XenoPort.com.
XenoPort is a registered trademark of XenoPort, Inc.
Horizant is a trademark of GlaxoSmithKline.